img
The evaluation of exposure to hepatitis A virus in HBsAg-positive persons: A multicentre study from Turkey    
Yazarlar
Mustafa Kemal Celen
Dicle University, Faculty of Medicine, Turkey
Kamuran Turker
Bağcilar Eğitim ve Araştirma Hastanesi, Turkey
Nefise Oztoprak
Antalya Education and Research Hospital, Turkey
Alper Sener
Çanakkale Onsekiz Mart Üniversitesi, Turkey
Nazan Tuna
Sakarya Üniversitesi, Turkey
Nevin Ince
Nevsehir State Hospital, Turkey
Ilknur Erdem
Tekirdağ Namık Kemal Üniversitesi, Turkey
Nese Saltoglu
Istanbul University-Cerrahpasa, Turkey
Davut Ozdemir
Düzce Üniversitesi, Turkey
Tuba Dal
Dicle University, Faculty of Medicine, Turkey
 Mustafa Kasım KARAHOCAGİL Mustafa Kasım KARAHOCAGİL
Kırşehir Ahi Evran Üniversitesi, Türkiye
Fatma Sirmatel
Bolu Abant İzzet Baysal Üniversitesi, Turkey
Fusun Zeynep Akcam
Isparta University of Applied Sciences, Turkey
Fatma Eksi Polat
Bağcilar Eğitim ve Araştirma Hastanesi, Turkey
Mehmet Cabalak
T. C. Sağlık Bakanlığı, Bingol Devlet Hastanesi, Turkey
Suzan Sacar
Çanakkale Onsekiz Mart Üniversitesi, Turkey
Selma Tosun
Manisa State Hospital, Turkey
Fehmi Tabak
Istanbul University-Cerrahpasa, Turkey
Özet
Chronic hepatitis B is a major public health problem in our country. Hepatitis A vaccination in HBV carriers who did not encounter with Hepatitis A virus is also significant. We aimed to evaluate the rate of exposure to HAV in HBsAg-positive persons, and the distribution of seronegative individuals according to age groups. Medical records of 4793 patients from 14 centers who were positive for hepatitis B surface antigen (HBsAg). A total 3514 cases (73.3%) were male and 1279 (26.7) were female. The HBsAg positive patients who were previously tested for HAV IgG at the time of firstly admitted to a center. HBsAg positive patients who were previously not tested for HAV IgG were tested and these . patients were confirmed serologically for HAV. The distribution of cases according to age were determined. In this study, 4793 HBsAg-positive patients were evaluated. The ratio of testing of anti-HAV IgG was very low during the first visit (54.2%). Seronegativity was highest in the age group under 19 years of age (26.2%) followed by 20-25 age group (15.5%) and 26-29 age group (12.5%). Testing of HAV serology should not be ignored in especially HBsAg-positive young adults and seronegative young adults should be vaccinated.
Anahtar Kelimeler
Anti-HAV IgG | HBsAg | Hepatitis A
Makale Türü Özgün Makale
Makale Alt Türü SCOPUS dergilerinde yayımlanan tam makale
Dergi Adı Journal of Pure and Applied Microbiology
Dergi ISSN 0973-7510
Makale Dili İngilizce
Basım Tarihi 08-2014
Cilt No 8
Sayı 4
Sayfalar 3063 / 3068
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
SCOPUS 4

Paylaş